The direct-to-employer (DTE) is an industry first for FDA-approved weight-loss drugs like Novo Nordisk's Wegovy (semaglutide) ...
Discover six obesity deals made so far in 2025, with dealmaking activity in the field being largely dominated by big pharma ...
1hon MSNOpinion
Making GLP-1 weight loss drugs cheaper isn’t enough to address America’s obesity problem – here’s why
The Trump administration is making a significant effort to reduce the cost of weight loss drugs. Its agreement with ...
Health, a leader in virtual cardiometabolic care, today announced a new offering designed to make access to obesity management medications and care more sustainable for employers. The "No-Barriers ...
Eli Lilly & Co. and Novo Nordisk A/S plan to start selling their popular obesity shots to employers through a new approach ...
Weight-loss drugs like Wegovy and Zepbound often cause nausea and other side effects. Brain scientists are looking for ways ...
In summary, under the Trump plan, the U.S. health system continues to fail Americans — by not viewing obesity as a disease, ...
Novo Nordisk (NVO) is deeply undervalued after a 43% YTD decline, despite strong fundamentals and global obesity market ...
You’re reading The Checkup With Dr. Wen, a newsletter on how to navigate medical and public health challenges. Click here to ...
Remedy Meds is an online consumer health and pharmacy platform that provides access to compounded glucagon-like peptide-one ...
U.S. researchers are beginning to identify clinical characteristics that distinguish “super responders” to GLP-1 weight-loss ...
Concurrently, Viking is conducting the Phase 3 VANQUISH-2 study of subcutaneous VK2735 in patients with type 2 diabetes who have obesity or are overweight. That trial is currently enrolling patients, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback